Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 78

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 78
---
, consultants, contractors,
customers and vendors, to establish and protect our rights to our technology and, to the best extent possible, control the access to and
distribution of our technology, software, documentation and other proprietary information, all of which offer only limited protection.
Where we have the right to do so under our agreements, we seek to protect our proprietary position by filing patent applications in the
United States, the United Kingdom and worldwide related to our novel technologies and products that are important to our business. The
patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions
and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial
value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. There can be no assurance that:

| • | the scope of our patents provides and will provide us with exclusivity with respect to any or all of our                                  
 product candidates and technologies, as well as any other technologies and/or products that address the same problems as our technologies 
 and product candidates by a different means, whether in the same manner as us or not;                                                     |

| • | pending or future patent applications will be issued as patents; |

| • | our patents, and/or those patents to which we are licensed, are and will remain valid and enforceable                                   
 and will not be subject to invalidity or revocation proceedings and that such proceedings will not result in a complete or partial loss 
 of rights;                                                                                                                              |

| • | our entitlement to exploit patents from time to time (including patents registered solely in our name                                 
 or our affiliates’ name or in the joint names of us or an affiliate and a third party or patents which are licensed to us) is and     
 will be sufficient to protect our core intellectual property rights against third parties, our commercial activities from competition 
 or to support comprehensively our ability to develop and market our proposed products either now or in the future;                    |

| • | the lack of any particular patents or rights to exploit any particular patents, and the scope of our patents,                              
 will not have a material adverse effect on our ability to develop and market our proposed product candidates, either now or in the future; |

| • | we have or will have the resources to pursue any infringer of: (i) patents registered in our name (whether                                         
 solely or jointly with a third party) from time to time; or (